In Depth 31 Jan 2024
New epilepsy drugs: what is in the pipeline?
…a global phase 3 program. Cell therapy candidate for drug-resistant epilepsy Based in South San Francisco, biotech company Neurona Therapeutics is currently developing an allogeneic cell therapy candidate for the…